Release Date: August 29, 2025

CME Track Expiration Date: August 29, 2026

Pharmacist Track Expiration Date: December 31, 2026

Activity Overview

Schizophrenia represents a major psychiatric disorder characterized by symptoms that frequently compromise daily functioning and diminish overall quality of life. While effective management can lead to improved patient outcomes, many individuals continue to struggle with persistent or residual symptoms, medication adherence challenges, and adverse drug reactions. In particular, poor adherence to oral antipsychotic treatment increases the likelihood of symptom recurrence and psychiatric hospitalization. To address these challenges, long-acting injectable (LAI) antipsychotic formulations have been developed that offer advantages, such as eliminating the need for daily medication administration, maintaining more stable drug levels in the bloodstream, and facilitating consistent clinical oversight.

This educational program brings together clinical experts to examine how long-acting injectable antipsychotics can be effectively utilized in schizophrenia treatment, emphasizing their therapeutic benefits and safety profiles while exploring optimal strategies for incorporating these medications into personalized patient care approaches.

This educational activity is an archive of the live virtual symposium held on July 12, 2025.

Target Audience

This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, pharmacists, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Review relevant clinical characteristics of long-acting injectable agents for schizophrenia
Integrate long-acting injectable medications into individualized management plans for patients with schizophrenia

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Physicians’ Education Resource^®, LLC, (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Physicians’ Education Resource^®, LLC, has approved this knowledge-based activity for 1.00 ACPE CE hour 0661-0000-25-009-L01-P. Eligibility for credits requires full attendance, engagement in the live activity, completion and submission of the learner's NABP ID #, month and day of birth, activity pre- and post-session questions, and the postactivity evaluation. This UAN # expires on December 31, 2026.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Teva and Johnson & Johnson.

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

GET STARTED WITH THIS PROGRAM:

Related Content